The article discusses the rise of GLP-1 drugs like Ozempic for weight management and their approval by the FDA in 2021. Research indicates these drugs have benefits beyond obesity treatment, potentially aiding in cognitive health and addiction. A recent study analyzed over 2.4 million participants and identified that GLP-1 drugs could decrease the risk of 42 health conditions. However, notable side effects were also reported, increasing the risk of 19 adverse health outcomes, emphasizing the need for cautious use despite their effectiveness.
We found that these drugs lowered risks of 42 health outcomes, nearly a quarter of the total that we analyzed.
Our findings highlight that GLP-1 drugs, while beneficial, also come with significant side effects and increased health risks.
Collection
[
|
...
]